Home » Authors » Jim Shrine

Articles by Jim Shrine

Swiss Firm GlycoVaxyn Raises $9.5M For Vaccine Programs

July 17, 2007

Swiss Firm GlycoVaxyn Raises $9.5M For Vaccine Programs

July 17, 2007

CODA Raises $7M In Series C For Protein Expression Platform

July 12, 2007

CODA Raises $7M In Series C For Protein Expression Platform

July 12, 2007

CureVac Completes €35M Round For mRNA Product Development

July 11, 2007

CureVac Completes 35M Round For mRNA Product Development

July 11, 2007

No Abstract

Reata Raises $25M In Series E To Fund Development Programs

July 9, 2007

Reata Raises $25M In Series E To Fund Development Programs

July 9, 2007

ViroPharma Starts Phase III Trial Of Camvia In Liver Transplants

July 6, 2007

ViroPharma Starts Phase III Trial Of Camvia In Liver Transplants

July 6, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 9, 2025.
FDA clears path for Boston Sci’s Bolt IVL to challenge J&J’s Shockwave
BioWorld MedTech
Boston Scientific Corp.’s up to $664 million acquisition of Bolt Medical Inc. closed just days after Bolt secured U.S. FDA 520(k) clearance for its intravascular...
Biopharma exempt from US reciprocal tariffs, but not untouched
BioWorld
At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
Remegen’s lupus drug surfaces with phase III myasthenia gravis data
BioWorld
Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug,...